Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted

被引：16
|
作者：
Sharfstein, Joshua M. [1 ]
Psaty, Bruce M. [2 ,3 ,4 ,5 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[3] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[4] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA
[5] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 315卷 / 10期
关键词：
CONFIDENTIALITY; TRIALS;
D O I：
10.1001/jama.2016.1461
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：984 / 986
页数：3
相关论文
共 50 条
  • [21] Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
    Verpeut, Jessica L.
    Bello, Nicholas T.
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) : 831 - 841
  • [22] Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports (vol 86, pg 646, 2020)
    Onakpoya, Igho J.
    Lee, J. J.
    Mahtani, K. R.
    Aronson, J. K.
    Heneghan, C. J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (06) : 1531 - 1533
  • [23] Effect of Naltrexone/Bupropion on Cardiovascular Events in Overweight and Obese Participants with Type 2 Diabetes and Cardiovascular Risk Factors in a Large, Randomized, Double-Blind Study
    Buse, John B.
    Smith, Steven R.
    Gilder, Kye
    Shan, Kevin
    Halseth, Amy
    DIABETES, 2017, 66 : A557 - A557
  • [24] Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
    Bello, Nicholas T.
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (07) : 549 - 552
  • [25] Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses
    Sposito, Andrei C.
    Bonilha, Isabella
    Luchiari, Beatriz
    Benchimol, Alexander
    Hohl, Alexandre
    Moura, Fabio
    Cercato, Cintia
    Geloneze, Bruno
    Nadruz, Wilson
    Aguilar-Salinas, Carlos
    Carvalho, Luiz Sergio F.
    OBESITY REVIEWS, 2021, 22 (06)
  • [26] Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome, L.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (11) : 1463 - 1465
  • [27] BUPROPION AND/OR NALTREXONE ARE NOT ASSOCIATED WITH INCREASED RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS: A NETWORK META-ANALYSIS OF ADDITIVE EFFECTS
    De Carvalho, L. S. F.
    Luchiari, B. M.
    Bonilha, I.
    Sposito, A.
    ATHEROSCLEROSIS, 2020, 315 : E9 - E9
  • [28] Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
    Grilo, Carlos M.
    Lydecker, Janet A.
    Fineberg, Sarah K.
    Moreno, Jorge O.
    Ivezaj, Valentina
    Gueorguieva, Ralitza
    AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (12): : 927 - 937
  • [29] Effect on Body Weight of Naltrexone/Bupropion in Overweight and Obese Participants with Type 2 Diabetes and Cardiovascular Risk Factors in a Large, Randomized, Double-Blind Study
    Smith, Steven R.
    Buse, John B.
    Gilder, Kye
    Shan, Kevin
    Halseth, Amy
    DIABETES, 2017, 66 : A556 - A556
  • [30] Effectiveness of Naltrexone/Bupropion (Contrave) for Weight Maintenance: COR-WM Study
    Chetty, Vasudhevan
    OBESITY, 2024, 32 : 98 - 98
12345